These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2543891)

  • 1. Some newer antimicrobial agents with antipseudomonal activity.
    Pritchard RC
    Med J Aust; 1989 Jun; 150(12):708-11, 714-5. PubMed ID: 2543891
    [No Abstract]   [Full Text] [Related]  

  • 2. [Urinary tract infections caused by Pseudomonas aeruginosa].
    Ohi Y; Goto T; Mizuma Y
    Nihon Rinsho; 1991 Oct; 49(10):2323-30. PubMed ID: 1660946
    [No Abstract]   [Full Text] [Related]  

  • 3. Antipseudomonal antibiotics.
    Giamarellou H; Antoniadou A
    Med Clin North Am; 2001 Jan; 85(1):19-42, v. PubMed ID: 11190351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quinolones in the pediatric patient.
    Poole MD
    Ear Nose Throat J; 1993 Feb; 72(2):162. PubMed ID: 8387005
    [No Abstract]   [Full Text] [Related]  

  • 5. [Chemical structure , anti-bacterial activity and pharmacokinetics of new quinolones].
    Matsumoto F; Nishiwaki K; Morita M
    Nihon Rinsho; 1991 Oct; 49(10):2291-8. PubMed ID: 1660945
    [No Abstract]   [Full Text] [Related]  

  • 6. Change in antipseudomonal carbapenem susceptibility in 25 hospitals across 9 years is not associated with the use of ertapenem.
    Eagye KJ; Nicolau DP
    J Antimicrob Chemother; 2011 Jun; 66(6):1392-5. PubMed ID: 21459897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relevance of in vitro antibacterial activities and pharmacokinetic properties of antipseudomonal beta-lactam antibiotics to their therapeutic effects on urinary tract infection caused by Pseudomonas aeruginosa P 9 in mice.
    Nakao M; Nishi T; Kondo M; Fugono T; Imada A; Tsuchiya K
    J Antibiot (Tokyo); 1984 Mar; 37(3):275-84. PubMed ID: 6427164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections.
    Giamarellou H; Galanakis N; Dendrinos C; Stefanou J; Daphnis E; Daikos GK
    Eur J Clin Microbiol; 1986 Apr; 5(2):232-5. PubMed ID: 2941288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinations of antibiotics against Pseudomonas aeruginosa.
    Baltch AL; Smith RP
    Am J Med; 1985 Jul; 79(1A):8-16. PubMed ID: 3927722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of an antimicrobial restriction program on Pseudomonas aeruginosa resistance to beta-lactams in a large teaching hospital.
    Regal RE; DePestel DD; VandenBussche HL
    Pharmacotherapy; 2003 May; 23(5):618-24. PubMed ID: 12741436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evaluation of antipseudomonal antimicrobic agents.
    Gilbert DN
    Antibiot Chemother (1971); 1985; 36():111-33. PubMed ID: 3923909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [In vitro sensitivity of 39 strains of Pseudomonas aeruginosa isolated from urine culture of hospitalized patients].
    Vanni M; Zucca C
    Minerva Med; 1986 Jun; 77(27):1289-92. PubMed ID: 3088493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Pseudomonas aeruginosa biofilms with a combination of fluoroquinolones and fosfomycin in a rat urinary tract infection model.
    Mikuniya T; Kato Y; Ida T; Maebashi K; Monden K; Kariyama R; Kumon H
    J Infect Chemother; 2007 Oct; 13(5):285-90. PubMed ID: 17982715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa?-Results of an in vitro study.
    Millar BC; Rendall JC; Downey DG; Moore JE
    J Clin Pharm Ther; 2018 Dec; 43(6):836-843. PubMed ID: 29959786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Quinolone antibacterials--oral preparation].
    Niki Y
    Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():348-51. PubMed ID: 17455644
    [No Abstract]   [Full Text] [Related]  

  • 16. Occurrence of antipseudomonal beta-lactams and aminoglycosides resistance in Pseudomonas aeruginosa during therapy.
    Pagani L; Scarabelli M; Cereda PM; Debiaggi M
    Microbiologica; 1987 Jan; 10(1):103-10. PubMed ID: 3106759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current therapies for pseudomonas aeruginosa.
    Giamarellou H; Kanellakopoulou K
    Crit Care Clin; 2008 Apr; 24(2):261-78, viii. PubMed ID: 18361945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa.
    Roveta S; Schito AM; Marchese A; Schito GC
    Int J Antimicrob Agents; 2005 Nov; 26(5):366-72. PubMed ID: 16216467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tobramycin therapy in renal failure.
    Derrington AW
    Med J Aust; 1974 Oct; 2(15):571-2. PubMed ID: 4214984
    [No Abstract]   [Full Text] [Related]  

  • 20. Synergism of ceftizoxime and tobramycin for Pseudomonas aeruginosa.
    Kim C; Schick DG; Ashley MA; Montgomerie JZ
    J Antimicrob Chemother; 1982 Nov; 10 Suppl C():57-62. PubMed ID: 6296030
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.